• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Johnson & Johnson (JNJ) Stock Rebounds While Earnings Power Keeps Eroding

    Simply Wall St·10/15/2026 01:26:23
    語音播報

    The market pushed Johnson & Johnson up about 2% today after the Q3 print, yet the real story is far less euphoric. Adjusted earnings per share slipped year over year, while a roughly US$7b stack of litigation and deal related charges compressed reported profit and left GAAP EPS at only US$0.09.

    Investors who came in after a weak 7 day and 30 day stretch just saw a relief bounce. The key question now is whether that single day pop reflects confidence in the underlying pharmaceuticals engine or a quick trade on headline guidance that does not account for the margin pressure underneath.

    If you want Johnson & Johnson healthcare exposure but are concerned about litigation risk and lower earnings power, consider screening for sturdier balance sheets and cleaner income statements with our list of solid balance sheet and fundamentals stocks (25 results)

    Q3 2026 Earnings Summary

    • Total Revenue (Q3 2026 vs. Q3 2025): US$25,399 million vs. US$23,993 million (up about 5.9%)
    • Net Income Excl. Extra Items (Q3 2026 vs. Q3 2025): US$210 million vs. US$5,152 million (down about 95.9%)
    • Basic EPS (Q3 2026 vs. Q3 2025): US$0.09 vs. US$2.14 (down about 96.0%)
    • Trailing 12 Month Basic EPS (Q3 2026 TTM vs. Q3 2025 TTM): US$6.64 vs. US$10.44 (down about 36.4%)

    Tired of scrolling through blocks of earnings figures and litigation charges for Johnson & Johnson? Get the full picture of the business in clean visuals, including a clear view of its valuation with our company report for Johnson & Johnson.

    NYSE:JNJ Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026
    NYSE:JNJ Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026

    Johnson & Johnson Bull Case: Pipeline Milestones vs Profit Squeeze

    Bulls argue Johnson & Johnson can use its pharma and MedTech pipeline to offset patent risk and lift margins over time. The quarter gives them real milestones on the revenue side. Oncology sales grew around 17% with CARVYKTI, TECVAYLI, TALVEY and RYBREVANT all gaining share, while TREMFYA, CAPLYTA and SPRAVATO each posted strong double digit growth. New launches such as ICOTYDE and INLEXZO are already seeing broad uptake and coverage, which supports the idea that recent approvals can replace aging blockbusters.

    The stress test comes in earnings power. Adjusted EPS declined about 7.5% and trailing 12 month basic EPS fell from US$10.44 to US$6.64. Roughly US$7b of charges, plus IPR&D, indicate that heavy deal activity and legal costs are still biting into profit. So the bullish narrative is hitting its product and data milestones, while the margin and cash story remains unproven.

    Reveal where the surface looks calm while the models quietly disagree on Johnson & Johnson's next big earnings inflection and see what the street is actually penciling in for the outer years with our analyst estimates for Johnson & Johnson.

    Johnson & Johnson Bears See Earnings Power Fraying

    Bearish investors argue Johnson & Johnson is sacrificing earnings power and balance sheet clarity to keep the growth story alive. This quarter gives them plenty to point to. Adjusted EPS slipped about 7.5% and trailing 12 month basic EPS moved from US$10.44 to US$6.64. That is a sizeable gap between what the pipeline is delivering on the top line and what is dropping to the bottom line.

    Concerns about legal and deal related drag also look justified. Roughly US$7b of talc and transaction items pushed GAAP EPS to just US$0.09 and management flagged Firefly and Sail dilution of US$0.64 per share in 2026 and US$1.36 in 2027. MedTech grew only 2.5% operationally, with surgery slightly lower and Abiomed soft, which falls short of the cleaner, self funding diversification story bears would want disproved.

    After a quarter where one off items, softer profit margins and insider selling all crowd the picture, it is worth asking whether the visible issues are the full story or just early symptoms. Review the independent risk analysis for Johnson & Johnson which shows 3 important warning signs

    Take Control Of Your Next Move

    When a single quarter leaves Johnson & Johnson’s share price jumping while earnings power looks under pressure, it helps to step back and track the trend instead of reacting to one headline. Register for free with Simply Wall St and add the stock to a Watchlist so you can watch price move against fair value estimates and wait for a setup that fits your plan. After you build a position, keep the signal and cut the noise by managing everything through your Portfolio Command Center so only the most important events and estimate changes hit your dashboard. Over the long haul, use the Community to see how other investors are interpreting the same data, spot early debates on risks or catalysts, and stay a step ahead when sentiment starts to turn.

    Seeking Fresh Alternatives Beyond Johnson & Johnson

    Some of the sharpest moves start quietly while attention stays glued to yesterday’s headlines. Scan fresh stock ideas before momentum takes off and early windows get caught. Consider researching potential opportunities that align with your goals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.